Iglu-A Oral Suspension Refreshing is a combination antacid formulation containing Magaldrate 480 mg, Simethicone 20 mg, and Oxetacaine 10 mg per dose, designed to provide rapid and effective relief from symptoms associated with hyperacidity and gastrointestinal discomfort. Magaldrate acts as a potent antacid by neutralizing excess gastric acid, thereby alleviating heartburn, acid indigestion, and gastric irritation. Simethicone serves as an anti-foaming agent that reduces bloating and discomfort caused by excess gas in the gastrointestinal tract by facilitating the coalescence and expulsion of gas bubbles. Oxetacaine, a local anesthetic, provides symptomatic relief by numbing the mucosal lining of the esophagus and stomach, reducing pain and discomfort associated with acid reflux and gastritis. Iglu-A Oral Suspension Refreshing is indicated for the symptomatic treatment of acid-related disorders including gastroesophageal reflux disease (GERD), dyspepsia, gastritis, and peptic ulcers. The oral suspension formulation ensures rapid onset of action and ease of administration, particularly beneficial for patients experiencing difficulty swallowing tablets. It is recommended to use Iglu-A as directed by a healthcare professional, with caution in patients with renal impairment or hypersensitivity to any component. This combination therapy offers a comprehensive approach to managing acid-related gastrointestinal symptoms effectively.